| Hazard Information | Back Directory | [Uses]
Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research[1][2][3]. | [in vivo]
Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) hemistrontium treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2]. | Animal Model: | C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2] | | Dosage: | 30 mg/kg, 300 mg/kg | | Administration: | Oral gavage; daily; for 19 or 11 days | | Result: | Significantly inhibited the progression of fibrosis throughout the lungs of the animals. |
| [References]
[1] Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. DOI:10.18433/j34608
[2] Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. DOI:10.3389/fphar.2017.00016
[3] Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. DOI:10.1093/ajhp/59.14.1333 |
|
|